Nurix and Roche Partner on BTK Degrader with $700M Upfront, $2.3B Milestones
NRIX•Nurix Therapeutics secured a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, receiving a $700 million upfront payment and eligibility for up to $2.3 billion in milestones. The agreement splits U.S. profits and losses equally, allocates development costs 40/60, and funds pivotal CLL trials plus Phase 2 studies in MS and CSU.
1. Collaboration Structure
Nurix and Roche will co-develop and co-commercialize bexobrutideg in the United States, sharing profits and losses equally. Outside the U.S., Roche will handle commercialization while Nurix receives royalties in the low- to high-teens. Development costs are split 40% by Nurix and 60% by Roche.
2. Clinical Development Program
The partnership builds on an ongoing pivotal Phase 2/3 program in chronic lymphocytic leukemia and plans combination regimens across B-cell malignancies. Expansion into immunology and neurology includes Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria to explore broader BTK degradation potential.
3. Bexobrutideg Mechanism and Advantages
Bexobrutideg is an oral, brain-penetrant BTK degrader that leverages the ubiquitin proteasome pathway to eliminate BTK protein, targeting both kinase activity and scaffolding functions. This catalytic degradation approach may overcome resistance mutations, sustain pharmacodynamic effects at low exposures, and improve safety versus conventional BTK inhibitors.
4. Financial Terms and Strategic Impact
Nurix will receive a $700 million upfront payment and can earn up to $2.3 billion in development, regulatory and sales milestones. This infusion strengthens Nurix’s cash runway, accelerates its evolution into a fully integrated biopharma company and enhances its global footprint in oncology, immunology and neurology.
